TY - JOUR
T1 - The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine
AU - Yu, Hua
AU - Li, Wen-Ming
AU - Kan, Kelvin K. W.
AU - Ho, Jason M. K.
AU - Carlier, Paul R.
AU - Pang, Yuan-Ping
AU - Gu, Zhe-Ming
AU - Zhong, Zuo
AU - Chan, Kelvin
AU - Wang, Yi-Tao
AU - Han, Yi-Fan
PY - 2008
Y1 - 2008
N2 - The lipophilicity and solubility profiles of bis(12)-hupyridone (B12H) and bis(7)-tacrine (B7T), two novel acetylcholinesterase inhibitors dimerized from huperzine A fragments and tacrine, respectively, were investigated over a broad pH range. Lipophilicity was assessed by both shake flask method with 1-octanol–water system and a reverse-phase HPLC system with methanol–water as mobile phase. The former method was used for determining the lipophilicities of the ionized forms (logD) of the dimers while the latter method was used for that of the neutral forms (log P). The log P values for B12H and B7T were found to be 5.4 and 8.2, respectively, indicating that the two dimers are highly lipophilic. The solubilities of both dimers were found to be affected by pH. The solubility of B12H was >1.41 mg/ml when the pH was <7, but <0.06 mg/ml when the pH was >8. The solubility of B7T was >0.26 mg/ml when the pH was <9, but <0.005 mg/ml when the pH was >12. The ionic strength of a solution could affect the solubilities considerably (11.16 mg/ml for B12H and 12.71 mg/ml for B7T in water; 2.07 mg/ml for B12H and 0.36 mg/ml for B7T in saline). The ionization constants (pKa) of the two dimers were determined by UV spectrophotometry. Both dimers were found to have two pKa values: 7.5±0.1 (pKa1) and 10.0±0.2 (pKa2) for B12H; and 8.7±0.1 (pKa1) and 10.7±0.4 (pKa2) for B7T. Furthermore, an in vivo pharmacological assay conducted in mice showed that a maximum AChE inhibition occurred 15 min after the single-dose and intraperitoneal administration of either dimer. This indicates that the two dimers may easily cross the blood–brain barrier. In summary, these physiochemical characteristics suggest that the two dimers may be promising candidates for the development of better drugs for Alzheimer’s disease.
AB - The lipophilicity and solubility profiles of bis(12)-hupyridone (B12H) and bis(7)-tacrine (B7T), two novel acetylcholinesterase inhibitors dimerized from huperzine A fragments and tacrine, respectively, were investigated over a broad pH range. Lipophilicity was assessed by both shake flask method with 1-octanol–water system and a reverse-phase HPLC system with methanol–water as mobile phase. The former method was used for determining the lipophilicities of the ionized forms (logD) of the dimers while the latter method was used for that of the neutral forms (log P). The log P values for B12H and B7T were found to be 5.4 and 8.2, respectively, indicating that the two dimers are highly lipophilic. The solubilities of both dimers were found to be affected by pH. The solubility of B12H was >1.41 mg/ml when the pH was <7, but <0.06 mg/ml when the pH was >8. The solubility of B7T was >0.26 mg/ml when the pH was <9, but <0.005 mg/ml when the pH was >12. The ionic strength of a solution could affect the solubilities considerably (11.16 mg/ml for B12H and 12.71 mg/ml for B7T in water; 2.07 mg/ml for B12H and 0.36 mg/ml for B7T in saline). The ionization constants (pKa) of the two dimers were determined by UV spectrophotometry. Both dimers were found to have two pKa values: 7.5±0.1 (pKa1) and 10.0±0.2 (pKa2) for B12H; and 8.7±0.1 (pKa1) and 10.7±0.4 (pKa2) for B7T. Furthermore, an in vivo pharmacological assay conducted in mice showed that a maximum AChE inhibition occurred 15 min after the single-dose and intraperitoneal administration of either dimer. This indicates that the two dimers may easily cross the blood–brain barrier. In summary, these physiochemical characteristics suggest that the two dimers may be promising candidates for the development of better drugs for Alzheimer’s disease.
KW - Alzheimer's disease
KW - solubility
UR - http://handle.uws.edu.au:8081/1959.7/551062
U2 - 10.1016/j.jpba.2007.08.027
DO - 10.1016/j.jpba.2007.08.027
M3 - Article
SN - 0731-7085
VL - 46
SP - 75
EP - 81
JO - Journal of Pharmaceutical and Biomedical Analysis
JF - Journal of Pharmaceutical and Biomedical Analysis
IS - 1
ER -